GSK3B and prostate cancer: Next, GSK-3β inhibition strongly attenuated the clonogenic capacity of tested prostate cancer cell lines PC-3 (68% inhibition), PC-3M-Pro4 (-97%), C4-2B4 (-94%) and DU-145 (-44%) (Fig. 2b).